Working... Menu

Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01467141
Recruitment Status : Completed
First Posted : November 8, 2011
Last Update Posted : February 23, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This trial is conducted in Europe. The aim of this trial is to evaluate safety and efficacy in children with type 1 diabetes.

Condition or disease Intervention/treatment Phase
Diabetes Diabetes Mellitus, Type 1 Drug: insulin aspart Drug: human insulin Drug: isophane human insulin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Meal-related Insulin Aspart Therapy Versus Meal-related Human Insulin Therapy in Children 2-6 Years of Age With Type 1 Diabetes Mellitus: A Multi-centre Randomised, Open-labelled, Cross-over, Safety and Efficacy Trial
Actual Study Start Date : June 19, 2002
Actual Primary Completion Date : October 15, 2003
Actual Study Completion Date : October 15, 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: IAsp Drug: insulin aspart
Injected s.c. (under the skin) three times a day

Drug: isophane human insulin
May be administered s.c. (under the skin) in both treatment groups thrice daily

Active Comparator: HI Drug: human insulin
Injected s.c. (under the skin) 30 minutes before the meals

Drug: isophane human insulin
May be administered s.c. (under the skin) in both treatment groups thrice daily

Primary Outcome Measures :
  1. Incidence of hypoglycaemic episodes during the treatment [ Time Frame: Week 0; week 24 ]
  2. Change in HbA1c (glycosylated haemoglobin A1c) [ Time Frame: Week 0; week 24 ]

Secondary Outcome Measures :
  1. Incidence of Adverse Events (AEs) [ Time Frame: Week 0; week 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 1 diabetes
  • Treatment with insulin for at least 6 months prior to inclusion
  • HbA1c below or equal to 11.0 %
  • Currently treated with short acting, intermediate acting, long acting human insulin or analogues or a self-mix of these insulins at least 1 month prior to inclusion

Exclusion Criteria:

  • The receipt of any investigational drug within one month prior to this trial
  • Recurrent severe hypoglycaemia or hypoglycaemic awareness as judged by the investigator
  • Total daily insulin doses at least 1.80 IU/kg
  • Treatment with oral hypoglycaemic agents
  • Known or suspected allergy to trial product or related products

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01467141

Layout table for location information
Novo Nordisk Investigational Site
Berlin, Germany, 13353
Novo Nordisk Investigational Site
Dresden, Germany, 01307
Novo Nordisk Investigational Site
Hagen, Germany, 58095
Novo Nordisk Investigational Site
Hamburg, Germany, 22149
Novo Nordisk Investigational Site
Hannover, Germany, 30173
Novo Nordisk Investigational Site
Osnabrück, Germany, 49082
Sponsors and Collaborators
Novo Nordisk A/S
Layout table for investigator information
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S

Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Novo Nordisk A/S Identifier: NCT01467141     History of Changes
Other Study ID Numbers: ANA-1415
First Posted: November 8, 2011    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin, Globin Zinc
Insulin Aspart
Insulin, Long-Acting
Insulin degludec, insulin aspart drug combination
Isophane Insulin, Human
Insulin, Isophane
Isophane insulin, beef
Hypoglycemic Agents
Physiological Effects of Drugs